Melanoma Spotlight

Melanoma Spotlight
Melanoma is the deadliest form of skin cancer, accounting for the majority of skin cancer deaths worldwide. 

While melanoma rates have been rising over the last 30 years, advancements in treatment and early detection are providing new hope for patients everywhere. In this edition of Guided By Science, we explore melanoma prevention, early detection, and new treatments that are changing the way we treat this deadly disease.

Combining Therapies to Treat Cancer
There’s never been a more exciting time for the field of cancer immunotherapy. New treatments are showing great promise and changing the way we think about cancer care.

At the forefront of this revolution is the idea of combining therapies to combat the many ways cancers can adapt and survive. As our understanding of cancer and the immune system grows, we are witnessing the emergence of a new vision – where practical combinations can benefit many more patients now faced with life-threatening disease.

Immunotherapy: A New Era in Cancer Care
Immunotherapies harness the natural power of our immune system to target and fight disease. Advancements in science and technology have brought about a new wave of promising cancer immunotherapies. This burgeoning field of immuno-oncology (IO) is revolutionizing how we perceive and treat cancer.

Presentations on December 6 to Cover ImmunoPulse Therapy and Phase II Study of Melanoma Patients 

SAN DIEGO – December 04, 2012 — OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced it will be presenting at the DNA Vaccines 2012 Conference at the Loews Coronado Bay Resort in San Diego, California. OncoSec is a Silver Sponsor of the conference.

The Company will conduct two presentations within the Cancer Immune Therapy Track on Thursday, December 6:

From 11:30 AM-12:00 PM PT, Richard Heller, Ph.D., director of the Frank Reidy Research Center for Bioelectrics at Old Dominion University, will speak on “Gene Electrotransfer for the Enhanced Delivery of Immunomodulating Agents.” In this presentation, Dr. Heller will present data on electroporation and delivery of plasmids for cancer immunotherapy, a technology used in OncoSec’s ImmunoPulse therapy.

From 12:00 PM-12:30 PM PT, Adil Daud, M.D., clinical professor of medicine and dermatology and director of the melanoma program at the University of California, San Francisco, will speak on “Clinical Studies of Melanoma Therapy.” In this presentation, Dr. Daud will be reviewing previously presented interim data from OncoSec’s ongoing Phase II trial for metastatic melanoma for which he is principal investigator.

The DNA Vaccines Conference brings in an array of researchers from all corners of the world to present new cutting-edge discoveries in DNA vaccines that have never before been presented or published at any other meeting. For more information about the conference, please visit: www.bioconferences.com/conferences/dna/index.aspx

 

 


Real Time Web Analytics